MYCN and neoplasm: In line with these findings, the specific AURKA inhibitor MLN8237 (alisertib) facilitated degradation of either MYC or its paralog MYCN by the FBXW7‐associated ubiquitin‐ligase complex SCFFBXW7, and induced tumor regression in preclinical studies [147, 150].